Skip to main content
. 2023 Feb 27;46(4):132–144. doi: 10.1097/CJI.0000000000000456

TABLE 1.

Summary of T-Cell Batches Used in This Study

%Vα24+ of CD3+ lymphocytes (%TCR+) %CD8α+ of CD4+ Vα24+
Batch Used in figures HLA-A*02:01 status ntd ADP-A2M4 ADP-A2M4CD8 ntd ADP-A2M4 ADP-A2M4CD8
Large scale
 L213 1, 2, 4, S1, S7 + 0.94 64.3 59 0 0.9 97.8
 L214 1, 4, S1, S4, S7 0.7 60.4 55 0 0 98.7
 L215 1, 4, 5, S1, S4, S7 0.8 44.4 44.1 0 2.89 98
 L216 1, 3–5, S1, S4, S6, S7 + 0.62 54.7 56.9 0 0 98.3
 L217 1–5, S1, S4, S6, S7 + 0.94 57.1 61.2 0 0 99
Small scale
 SS1 3, S6 + 0.76 54.8 58.3 0 0 98.6
 SS2 3, S6 + 1.04 45.3 44.9 0 0.24 98.1
 SS3 2 + 0.79 52.6 50.1 0.64 0.012 98.6
 SS4 2 + 0.95 42.9 46.9 0 0.11 98.3

Small-scale and large-scale T-cell batches used in the study. Each batch was manufactured from a different healthy donor. HLA-A*02:01 status, TCR transduction efficiency (%Vα24), and expression of CD8α within CD4+ Vα24+ population of T cells are also described for each product.

ntd, nontransduced; S, Supplemental; TCR, T-cell receptor.